Last updated 2026-07-20
- Acquired by Roche for $3.5B, Oct 2025
Total raised
—
Last: A Round 2018-10
Stage
Acquired
Founded
2018
Headcount
93
HQ
San Francisco, United States
Sector
Health Tech & Life Sciences
About
89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. The company's lead product candidate, pegozafermin (formerly BIO89-100), is an investigational glycoPEGylated FGF21 analog being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). 89bio was founded in Israel in 2018 and is currently headquartered in the U.S., with an R&D center in Israel.
Headcount over time
93 employees (2026-09) · 1 point
Offices
San Francisco, United States · HQ / main office
Q&A
- What is 89bio's primary focus?
- 89bio is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases.
- What is 89bio's lead product candidate?
- 89bio's lead product candidate is pegozafermin (BIO89-100), an investigational glycopegylated FGF21 analog.
- What conditions is pegozafermin being evaluated for?
- Pegozafermin is currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
- When was 89bio founded?
- 89bio was founded in January 2018.
- What is 89bio's current market capitalization?
- 89bio's market capitalization is $2,203,627,632 USD.
- What is the total amount of funding 89bio has raised?
- 89bio has raised a total of $1,146,000,000 USD.
- When was 89bio's last funding round and who were the investors?
- 89bio's last funding round occurred in October 2018, with investors including RA Capital Management and Pontifax.
- What is the current status of 89bio?
- 89bio is currently active and was acquired by Roche in September 2025.
Team · 10
Michal Ayalon
Founder · Head of R&D
Ram Waisbourd
Founder · COO and Chief Business Officer
Rohan Palekar
Chief Executive Officer
Michael Hayden
Founding Board Member
Anat Naschitz
Managing Director, OrbiMed
Steve Squinto
Venture Partner, OrbiMed
Greg Grunberg
Managing Director, Longitude Capital
Derek DiRocco
RA Capital Management
Tomer Kariv
Pontifax
Hank Mansbach
Chief Medical Officer
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
Patents
Tags
biopharmaceuticaldiabetespharmaceuticalsbiotechnologylife-sciencespatientsgastroenterology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | 89bio.com |
|---|---|
| linkedin.com/company/54350802 | |
| Wikipedia | he.wikipedia.org/wiki/89%D7%91%D7%99%D7%95 |
| Wikidata | wikidata.org/wiki/Q136365899 |
Identifiers & details
| Legal name | 89bio, Inc. |
|---|---|
| Founded | 2018-1 |
| Employees (exact) | 93 |
| Wikidata QID | Q136365899 |
Acquisitions & public offerings
Acquired by Roche 2025-10 $3.5B
Radar intelligence
Patents
| EPO | 13 |
|---|
Publications (Crossref)
| Works | 8 |
|---|
Web history (Wayback)
| Domain | 89bio.com |
|---|
Wikidata
| QID | Q136365899 |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515789352 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2018-01-31 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 6 — charge (2), violation (1), people (3) |
| Registered address | אופנהיימר 4 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-10-30 | סילוק שעבוד |
| 2025-10-30 | סילוק שעבוד |
| 2026-06-25 | עדכון הפרה |
| 2026-01-20 | עדכון בעלי תפקידים |
| 2026-03-11 | עדכון דירקטורים-הוספת דירקטור |
| 2026-03-11 | עדכון דירקטורים-הסרת דירקטור |